All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Junshi Biosciences' toripalimab (targeting PD-1) with bevacizumab (targeting VEGF-A) approved by Chinese NMPA for first-line treatment of unresectable or metastatic hepatocellular carcinoma
Monoclonal antibody, hepatocellular carcinoma, cancer, combo therapy - Read more

THE GOOD
Business Development

Novo Nordisk in-licenses Chinese biotech United Laboratories' UBT251 (glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptor agonist) for up to $2B, setting up competition with Eli Lilly's retatrutide
Peptide, GLP-1, obesity, type 2 diabetes - Read more

PRESENTED BY YOU?
Get the attention of 1800+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

CG Oncology's cretostimogene (CSF-2R stimulant) shows 75.5% complete response rate in Ph3 trial for high-risk non-muscle invasive bladder cancer with carcinoma in situ
Oncolytic virus, bladder cancer - Read more

THE GOOD
Fundraises

CBC Group $1B Healthcare Buyout Fund, raising Asia's largest healthcare fund for biopharma, medical devices, and healthcare services
Venture capital, biotech investing, healthcare investing - Read more

Augustine Therapeutics €77.7M ($84.1M) Series A, developing therapies through HDAC6 enzyme inhibition for Charcot-Marie-Tooth disease treatment
Small molecule, Charcot-Marie-Tooth disease - Read more

Tempero Bio $70M Series B, developing therapies for substance use disorders with focus on alcohol and cocaine addictions
Small molecule, substance-use disorder, alcohol use disorder, cocaine-use disorder - Read more

Surrozen $175M private placement, developing Wnt-targeted therapeutics for retinopathies and eye diseases
Bispecific fusion protein, eye disease, ophthalmology - Read more

Opus Genetics $20M public offering and $1.5M private placement, developing gene therapies for inherited retinal diseases
Gene therapy, ophthalmology, eye disease, AAV, Leber congenital amaurosis 5 (LCA5), bestrophinopathies - Read more

TransCode Therapeutics $10M registered direct offering, developing RNA therapeutics for metastatic cancer treatment with TTX-MC138 and other candidates
RNA, nanoparticle, cancer - Read more

USDA $100M funding initiative to combat avian flu through therapeutics and research supporting farmers
Vaccine, bird flu (H5N1/avian flu), public funding - Read more

THE GOOD
Investments

Biogen consolidates Massachusetts operations at new Cambridge headquarters in MIT's Kendall Common
New facility, company creation/building, headquarters - Read more

$5M Canadian government funding to help Neptune BioInnovation create Canada's first large-scale bioinnovation hub in Dartmouth, Nova Scotia
Facility expansion, company creation/building, CDMO (Contract Development & Manufacturing Organization), biomanufacturing, public funding - Read more

THE GOOD
Partnerships

PolTREG, Antion Biosciences strategic partnership developing allogeneic off-the-shelf CAR-Treg therapies for autoimmune/neurodegenerative diseases.
Cell therapy, allogeneic cell therapy, regulatory T-cell (Treg), CAR-Treg, autoimmune disease, neurodegenerative disease, drug development - Read more

Abbisko Therapeutics, Allist Pharmaceuticals partnering to explore ABSK043 (targeting PD-L1) and glecirasib (KRAS G12C inhibitor) combination therapy for KRAS-G12C mutated NSCLC
Small molecule, combo therapy, lung cancer, clinical development - Read more

THE GOOD
Public Health

Valneva delivering 40,000 chikungunya vaccine doses to Réunion amid outbreak, prioritizing vulnerable older adults with co-morbidities
Low- and middle-income countries, vaccine, Chikungunya virus - Read more

THE GOOD
Research

Study points towards combining statins with ezetimibe significantly reduces cardiovascular deaths and lowers cholesterol more effectively than statins alone
Myocardial infarction (heart attack), small molecule, cholesterol - Read more

PRESENTED BY TLDR BIOTECH
What would you do with 6.5k+ meticulously tagged biotech & pharma data points?
*New* Sample Data Available - See below!

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

Here’s a sample set of data - lung cancer stories over the last 3 months.

If you’re interested, send us an email [email protected] with the subject line “6K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

THE BAD
Clinical Trials

Opthea's sozinibercept (VEGF-C/D inhibitor) + Eylea (anti-VEGF-A) flops in Ph3 wet AMD trial versus Eylea alone
Fusion protein, wet age-related macular degeneration (wet AMD), combo therapy - Read more

Unity Biotechnology's UBX1325 (BCL-xL inhibitor) misse Ph2b primary endpoint against Eylea in Ph2b trial for diabetic macular edema
Small molecule, diabetic macular edema - Read more

THE BAD
Lawsuits

AbbVie sues Genmab, alleging trade secret theft of ADC technology via recently acquired ProfoundBio
Antibody-drug conjugate (ADC), trade secrets - Read more

THE BAD
Strategic Plans

Surrozen discontinues hepatitis drug SZN-043 (R-Spondin mimetic) due to insufficient clinical benefits, pivots to eye disease pipeline instead
Pipeline strategy, bispecific fusion protein, alcohol-associated hepatitis, eye disease - Read more

THE UGLY
Earnings & Finances

23andMe files for bankruptcy, CEO Anne Wojcicki resigns
Genetic screening, at-home testing, consumer health, bankruptcy - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here